dosage adjustment of Daclizumab in renal failure




Daclizumab.JPG

Daclizumab

CLINICAL USE

Humanised murine/human monoclonal anti-CD25 antibody:Prophylaxis of acute allograft rejection, in combination with maintenance immunosuppressants

DOSE IN NORMAL RENAL FUNCTION

1 mg/kg within 24 hours of transplantation, then 1 mg/kg every 14 days for 5 doses. See ‘Other Information’

PHARMACOKINETICS

  • Molecular weight                           :144 000
  • %Protein binding                           :No data
  • %Excreted unchanged in urine     : No data
  • Volume of distribution (L/kg)       :5.3 litres
  • half-life – normal/ESRD (hrs)      :270–919/–

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50     : Dose as in normal renal function
  • 10 to 20     : Dose as in normal renal function
  • <10           : Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD                :Not dialysed. Dose as in normal renal function
  • HD                     :Not dialysed. Dose as in normal renal function
  • HDF/high flux   :Unknown dialysability. Dose as in normal renal function
  • CAV/VVHD      :Unlikely to be dialysed. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugsNone known

    ADMINISTRATION

    Reconstition

    Route

    IV infusion

    Rate of Administration

    Over 15 minutes

    Comments

    Add required dose to 50 mL of sodium chloride 0.9%Stable for 24 hours at 2–8°C if prepared aseptically

    OTHER INFORMATION

    An alternative dosing regimen that may be used is 2 mg/kg every 14 days for 2 doses